Asthma in Adults

To the Editor: To bring focus to discrepancies in asthma-related incidence, morbidity, and mortality falling along socioeconomic lines, the inequity in the availability of guideline-concordant care should be noted in the Clinical Practice article by Mosnaim (Sept. 14 issue).1 The inhaled glucocorticoid–formoterol combination, as recommended in the Global Initiative for Asthma (GINA) 2023 track 1 guidelines for first-line therapy, is often unattainable,2 especially for underinsured and uninsured persons. In a sad juxtaposition, the most available (and sole) over-the-counter medication for asthma that has been approved by the Food and Drug Administration is an epinephrine metered-dose inhaler, which has not been . . .